These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
303 related articles for article (PubMed ID: 35165274)
1. Clinical and biomarker analyses of sintilimab versus chemotherapy as second-line therapy for advanced or metastatic esophageal squamous cell carcinoma: a randomized, open-label phase 2 study (ORIENT-2). Xu J; Li Y; Fan Q; Shu Y; Yang L; Cui T; Gu K; Tao M; Wang X; Cui C; Xu N; Xiao J; Gao Q; Liu Y; Zhang T; Bai Y; Li W; Zhang Y; Dai G; Ma D; Zhang J; Bai C; Huang Y; Liao W; Wu L; Chen X; Yang Y; Wang J; Ji S; Zhou H; Wang Y; Ma Z; Wang Y; Peng B; Sun J; Mancao C Nat Commun; 2022 Feb; 13(1):857. PubMed ID: 35165274 [TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety evaluation of frontline immunotherapy combinations in advanced esophageal squamous cell carcinoma: a network meta-analysis highlighting the value of PD-L1 expression positivity scores. Chen W; Cao K; Zhang L; Zhao X; Chen B; Li W; Shang R; Sun L; Jiang Z; Wang J; Xue W Front Immunol; 2024; 15():1414753. PubMed ID: 39050848 [TBL] [Abstract][Full Text] [Related]
3. Camrelizumab versus investigator's choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study. Huang J; Xu J; Chen Y; Zhuang W; Zhang Y; Chen Z; Chen J; Zhang H; Niu Z; Fan Q; Lin L; Gu K; Liu Y; Ba Y; Miao Z; Jiang X; Zeng M; Chen J; Fu Z; Gan L; Wang J; Zhan X; Liu T; Li Z; Shen L; Shu Y; Zhang T; Yang Q; Zou J; Lancet Oncol; 2020 Jun; 21(6):832-842. PubMed ID: 32416073 [TBL] [Abstract][Full Text] [Related]
4. Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma: The ESCORT-1st Randomized Clinical Trial. Luo H; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Shen Y; Yang Q; Zou J; Xu RH; JAMA; 2021 Sep; 326(10):916-925. PubMed ID: 34519801 [TBL] [Abstract][Full Text] [Related]
5. Randomized Phase III KEYNOTE-181 Study of Pembrolizumab Versus Chemotherapy in Advanced Esophageal Cancer. Kojima T; Shah MA; Muro K; Francois E; Adenis A; Hsu CH; Doi T; Moriwaki T; Kim SB; Lee SH; Bennouna J; Kato K; Shen L; Enzinger P; Qin SK; Ferreira P; Chen J; Girotto G; de la Fouchardiere C; Senellart H; Al-Rajabi R; Lordick F; Wang R; Suryawanshi S; Bhagia P; Kang SP; Metges JP; J Clin Oncol; 2020 Dec; 38(35):4138-4148. PubMed ID: 33026938 [TBL] [Abstract][Full Text] [Related]
6. PD-1 inhibitors versus chemotherapy as second-line treatment for advanced esophageal squamous cell carcinoma: a meta-analysis. Zhu X; Shanzhou Q; Li D; Pang X; Ma D BMC Cancer; 2021 Nov; 21(1):1195. PubMed ID: 34758782 [TBL] [Abstract][Full Text] [Related]
7. The effect of liver metastases on clinical efficacy of first-line programmed death-1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM-007 and meta-analysis. Gao J; Song Y; Kou X; Tan Z; Zhang S; Sun M; Zhou J; Fan M; Zhang M; Song Y; Li S; Yuan Y; Zhuang W; Zhang J; Zhang L; Jiang H; Gu K; Ye H; Ke Y; Qi X; Wang Q; Zhu J; Huang J Cancer Med; 2024 May; 13(10):e7203. PubMed ID: 38769930 [TBL] [Abstract][Full Text] [Related]
8. Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): multicentre, randomised, double blind, phase 3 trial. Lu Z; Wang J; Shu Y; Liu L; Kong L; Yang L; Wang B; Sun G; Ji Y; Cao G; Liu H; Cui T; Li N; Qiu W; Li G; Hou X; Luo H; Xue L; Zhang Y; Yue W; Liu Z; Wang X; Gao S; Pan Y; Galais MP; Zaanan A; Ma Z; Li H; Wang Y; Shen L; BMJ; 2022 Apr; 377():e068714. PubMed ID: 35440464 [TBL] [Abstract][Full Text] [Related]
9. Final analysis of camrelizumab plus chemotherapy for untreated advanced or metastatic esophageal squamous cell carcinoma: The ESCORT-1st trial. He M; Wang Z; Lu J; Bai Y; Mao T; Wang J; Fan Q; Zhang Y; Zhao K; Chen Z; Gao S; Li J; Fu Z; Gu K; Liu Z; Wu L; Zhang X; Feng J; Niu Z; Ba Y; Zhang H; Liu Y; Zhang L; Min X; Huang J; Cheng Y; Wang D; Sheng Z; Zeng W; Song L; Xu RH; Luo H Med; 2024 Sep; 5(9):1137-1149.e3. PubMed ID: 38870932 [TBL] [Abstract][Full Text] [Related]
10. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Kato K; Cho BC; Takahashi M; Okada M; Lin CY; Chin K; Kadowaki S; Ahn MJ; Hamamoto Y; Doki Y; Yen CC; Kubota Y; Kim SB; Hsu CH; Holtved E; Xynos I; Kodani M; Kitagawa Y Lancet Oncol; 2019 Nov; 20(11):1506-1517. PubMed ID: 31582355 [TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitors as the second-line treatment for advanced esophageal squamous cell carcinoma: a cost-effectiveness analysis based on network meta-analysis. Yang X; Zheng X; Hu S; Huang J; Zhang M; Huang P; Wang J BMC Cancer; 2024 May; 24(1):654. PubMed ID: 38811891 [TBL] [Abstract][Full Text] [Related]
12. Clinical features and treatment outcomes of PD-1 inhibitor therapy in elderly patients (≥ 65 years) with advanced esophageal squamous cell carcinoma: a real-world study. Yu Y; Wu T; Gan W; Liu C; Zhang R; Zheng J; Xiong J; Chen J; Li J Clin Transl Oncol; 2024 Sep; 26(9):2360-2368. PubMed ID: 38602642 [TBL] [Abstract][Full Text] [Related]
13. Pembrolizumab versus chemotherapy for patients with esophageal squamous cell carcinoma enrolled in the randomized KEYNOTE-181 trial in Asia. Cao Y; Qin S; Luo S; Li Z; Cheng Y; Fan Y; Sun Y; Yin X; Yuan X; Li W; Liu T; Hsu CH; Lin X; Kim SB; Kojima T; Zhang J; Lee SH; Bai Y; Muro K; Doi T; Bai C; Gu K; Pan HM; Bai L; Yang JW; Cui Y; Lu W; Chen J ESMO Open; 2022 Feb; 7(1):100341. PubMed ID: 34973513 [TBL] [Abstract][Full Text] [Related]
14. Recombinant human endostatin plus paclitaxel/nedaplatin for recurrent or metastatic advanced esophageal squamous cell carcinoma: a prospective, single-arm, open-label, phase II study. Wang ZQ; Wang DS; Wang FH; Ren C; Tan Q; Li YH Invest New Drugs; 2021 Apr; 39(2):516-523. PubMed ID: 33070249 [TBL] [Abstract][Full Text] [Related]
15. Tislelizumab versus chemotherapy as second-line treatment for European and North American patients with advanced or metastatic esophageal squamous cell carcinoma: a subgroup analysis of the randomized phase III RATIONALE-302 study. Ajani J; El Hajbi F; Cunningham D; Alsina M; Thuss-Patience P; Scagliotti GV; Van den Eynde M; Kim SB; Kato K; Shen L; Li L; Ding N; Shi J; Barnes G; Van Cutsem E ESMO Open; 2024 Jan; 9(1):102202. PubMed ID: 38118368 [TBL] [Abstract][Full Text] [Related]
16. Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study. Shen L; Kato K; Kim SB; Ajani JA; Zhao K; He Z; Yu X; Shu Y; Luo Q; Wang J; Chen Z; Niu Z; Zhang L; Yi T; Sun JM; Chen J; Yu G; Lin CY; Hara H; Bi Q; Satoh T; Pazo-Cid R; Arkenau HT; Borg C; Lordick F; Li L; Ding N; Tao A; Shi J; Van Cutsem E; J Clin Oncol; 2022 Sep; 40(26):3065-3076. PubMed ID: 35442766 [TBL] [Abstract][Full Text] [Related]
17. Clinical Efficacy of Taxol Plus Platinum (TP) Chemotherapy Combined with Delayed Administration of PD-1 Inhibitors in Patients with Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study. Shen L; Chen Z; Zhang Z; Wu Y; Ren Y; Li Y; Li Y; Yin X; Han F; Chen Y Drug Des Devel Ther; 2024; 18():2761-2773. PubMed ID: 38979399 [TBL] [Abstract][Full Text] [Related]
18. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study. Ren Z; Xu J; Bai Y; Xu A; Cang S; Du C; Li Q; Lu Y; Chen Y; Guo Y; Chen Z; Liu B; Jia W; Wu J; Wang J; Shao G; Zhang B; Shan Y; Meng Z; Wu J; Gu S; Yang W; Liu C; Shi X; Gao Z; Yin T; Cui J; Huang M; Xing B; Mao Y; Teng G; Qin Y; Wang J; Xia F; Yin G; Yang Y; Chen M; Wang Y; Zhou H; Fan J; Lancet Oncol; 2021 Jul; 22(7):977-990. PubMed ID: 34143971 [TBL] [Abstract][Full Text] [Related]
19. Second-line tislelizumab versus chemotherapy in Japanese patients with advanced or metastatic esophageal squamous cell carcinoma: subgroup analysis from RATIONALE-302. Hara H; Satoh T; Kojima T; Tsushima T; Sunakawa Y; Okada M; Ding N; Wu H; Li L; Yu T; Barnes G; Kato K Esophagus; 2024 Apr; 21(2):102-110. PubMed ID: 38240916 [TBL] [Abstract][Full Text] [Related]
20. Impact of Pembrolizumab Versus Chemotherapy as Second-Line Therapy for Advanced Esophageal Cancer on Health-Related Quality of Life in KEYNOTE-181. Adenis A; Kulkarni AS; Girotto GC; de la Fouchardiere C; Senellart H; van Laarhoven HWM; Mansoor W; Al-Rajabi R; Norquist J; Amonkar M; Suryawanshi S; Bhagia P; Metges JP J Clin Oncol; 2022 Feb; 40(4):382-391. PubMed ID: 34730989 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]